

Anthony Ades

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1351752/publications.pdf>

Version: 2024-02-01

73
papers

9,221
citations

126858

33
h-index

85498

71
g-index

74
all docs

74
docs citations

74
times ranked

10284
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. <i>BMC Medical Research Methodology</i> , 2012, 12, 9.	1.4	1,465
2	Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. <i>Research Synthesis Methods</i> , 2012, 3, 98-110.	4.2	1,283
3	Evidence Synthesis for Decision Making 2. <i>Medical Decision Making</i> , 2013, 33, 607-617.	1.2	899
4	Assessing Evidence Inconsistency in Mixed Treatment Comparisons. <i>Journal of the American Statistical Association</i> , 2006, 101, 447-459.	1.8	631
5	Evidence Synthesis for Decision Making 4. <i>Medical Decision Making</i> , 2013, 33, 641-656.	1.2	513
6	Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2014, 1, 368-376.	3.7	484
7	Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. <i>Research Synthesis Methods</i> , 2016, 7, 80-93.	4.2	372
8	Evidence Synthesis for Decision Making 3. <i>Medical Decision Making</i> , 2013, 33, 618-640.	1.2	371
9	The natural history of <i>Chlamydia trachomatis</i> infection in women: a multi-parameter evidence synthesis. <i>Health Technology Assessment</i> , 2016, 20, 1-250.	1.3	358
10	Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2006, 24, 1-19.	1.7	352
11	Minimal clinically important difference on the Beck Depression Inventory - II according to the patient's perspective. <i>Psychological Medicine</i> , 2015, 45, 3269-3279.	2.7	202
12	Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. <i>Medical Decision Making</i> , 2018, 38, 200-211.	1.2	196
13	Evidence Synthesis for Decision Making 1. <i>Medical Decision Making</i> , 2013, 33, 597-606.	1.2	137
14	A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. <i>Statistics in Medicine</i> , 2003, 22, 2995-3016.	0.8	109
15	Meta-analysis of mixed treatment comparisons at multiple follow-up times. <i>Statistics in Medicine</i> , 2007, 26, 3681-3699.	0.8	92
16	Evidence Synthesis for Decision Making 7. <i>Medical Decision Making</i> , 2013, 33, 679-691.	1.2	79
17	The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. <i>Lancet Psychiatry</i> , 2019, 6, 903-914.	3.7	78
18	Evidence Synthesis for Decision Making 5. <i>Medical Decision Making</i> , 2013, 33, 657-670.	1.2	74

#	ARTICLE	IF	CITATIONS
19	Absolute or relative effects? Arm-based synthesis of trial data. <i>Research Synthesis Methods</i> , 2016, 7, 23-28.	4.2	74
20	Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. <i>Research Synthesis Methods</i> , 2011, 2, 43-60.	4.2	72
21	Accounting for correlation in network meta-analysis with multi-arm trials. <i>Research Synthesis Methods</i> , 2012, 3, 142-160.	4.2	61
22	Network Meta-Analysis with Competing Risk Outcomes. <i>Value in Health</i> , 2010, 13, 976-983.	0.1	55
23	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. <i>BMJ, The</i> , 2014, 349, g5741-g5741.	3.0	55
24	Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part B: Placing back-calculations in a formal statistical framework. <i>Science of the Total Environment</i> , 2014, 487, 642-650.	3.9	48
25	Extrapolation of Survival Curves from Cancer Trials Using External Information. <i>Medical Decision Making</i> , 2017, 37, 353-366.	1.2	48
26	Population Adjustment Methods for Indirect Comparisons: A Review of National Institute for Health and Care Excellence Technology Appraisals. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 221-228.	0.2	45
27	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. <i>Medical Decision Making</i> , 2015, 35, 859-871.	1.2	44
28	Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of Uncertainty. <i>Medical Decision Making</i> , 2002, 22, 359-371.	1.2	44
29	Symptom lead times in lung and colorectal cancers: what are the benefits of symptom-based approaches to early diagnosis?. <i>British Journal of Cancer</i> , 2015, 112, 271-277.	2.9	43
30	Symptom lead time distribution in lung cancer: natural history and prospects for early diagnosis. <i>International Journal of Epidemiology</i> , 2014, 43, 1865-1873.	0.9	42
31	Evidence Synthesis for Decision Making 6. <i>Medical Decision Making</i> , 2013, 33, 671-678.	1.2	41
32	Proportion of Pelvic Inflammatory Disease Cases Caused by <i>Chlamydia trachomatis</i> : Consistent Picture From Different Methods. <i>Journal of Infectious Diseases</i> , 2016, 214, 617-624.	1.9	40
33	Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study. <i>Statistics in Medicine</i> , 2020, 39, 4885-4911.	0.8	40
34	Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 537-545.	4.6	38
35	Survival Time Outcomes in Randomized, Controlled Trials and Meta-Analyses: The Parallel Universes of Efficacy and Cost-Effectiveness. <i>Value in Health</i> , 2011, 14, 640-646.	0.1	34
36	Strategies for Efficient Computation of the Expected Value of Partial Perfect Information. <i>Medical Decision Making</i> , 2014, 34, 327-342.	1.2	32

#	ARTICLE	IF	CITATIONS
37	Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes” Network meta-analysis of randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1192-1200.	1.2	31
38	Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. <i>Critical Care</i> , 2014, 18, 649.	2.5	24
39	Problem drug use prevalence estimation revisited: heterogeneity in capture”recapture and the role of external evidence. <i>Addiction</i> , 2016, 111, 438-447.	1.7	24
40	Quantifying how diagnostic test accuracy depends on threshold in a meta”analysis. <i>Statistics in Medicine</i> , 2019, 38, 4789-4803.	0.8	24
41	Selecting the best scale for measuring treatment effect in a network meta”analysis: a case study in childhood nocturnal enuresis. <i>Research Synthesis Methods</i> , 2012, 3, 126-141.	4.2	21
42	The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis. <i>PLoS ONE</i> , 2015, 10, e0140704.	1.1	21
43	Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes. <i>Medical Decision Making</i> , 2014, 34, 352-365.	1.2	20
44	A threshold analysis assessed the credibility of conclusions from network meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2016, 80, 68-76.	2.4	20
45	Estimating the prevalence of problem drug use from drug”related mortality data. <i>Addiction</i> , 2020, 115, 2393-2404.	1.7	20
46	Simultaneous Multioutcome Synthesis and Mapping of Treatment Effects to a Common Scale. <i>Value in Health</i> , 2014, 17, 280-287.	0.1	18
47	Simultaneous synthesis of treatment effects and mapping to a common scale: an alternative to standardisation. <i>Research Synthesis Methods</i> , 2015, 6, 96-107.	4.2	18
48	Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study. <i>EBioMedicine</i> , 2021, 68, 103414.	2.7	17
49	Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies. <i>Research Synthesis Methods</i> , 2010, 1, 239-257.	4.2	16
50	Indirect and mixed treatment comparisons in arthritis research. <i>Rheumatology</i> , 2011, 50, iv5-iv9.	0.9	16
51	Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses. <i>Medical Decision Making</i> , 2015, 35, 608-621.	1.2	16
52	Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England. <i>Epidemiology and Infection</i> , 2017, 145, 208-215.	1.0	15
53	A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 496.	0.7	15
54	Researching Zika in pregnancy: lessons for global preparedness. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e61-e68.	4.6	15

#	ARTICLE	IF	CITATIONS
55	The relative responsiveness of test instruments can be estimated using a meta-analytic approach: an illustration with treatments for depression. <i>Journal of Clinical Epidemiology</i> , 2016, 77, 68-77.	2.4	14
56	Equivalence of entropy balancing and the method of moments for matching-adjusted indirect comparison. <i>Research Synthesis Methods</i> , 2020, 11, 568-572.	4.2	14
57	Which Health-Related Quality-of-Life Outcome When Planning Randomized Trials: Disease-Specific or Generic, or Both? A Common Factor Model. <i>Value in Health</i> , 2013, 16, 185-194.	0.1	13
58	Use of a random effects meta-analysis in the design and analysis of a new clinical trial. <i>Statistics in Medicine</i> , 2018, 37, 4665-4679.	0.8	12
59	Incidence of <i>Chlamydia trachomatis</i> infection in women in England: two methods of estimation. <i>Epidemiology and Infection</i> , 2014, 142, 562-576.	1.0	10
60	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. <i>Rheumatology and Therapy</i> , 2015, 2, 113-125.	1.1	10
61	Target estimands for efficient decision making: Response to comments on "Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study". <i>Statistics in Medicine</i> , 2021, 40, 2759-2763.	0.8	10
62	Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia. <i>BMJ Open</i> , 2020, 10, e035307.	0.8	10
63	Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment. <i>Clinical Infectious Diseases</i> , 2023, 76, 913-991.	2.9	9
64	Overall Vertical Transmission of Hepatitis C Virus, Transmission Net of Clearance, and Timing of Transmission. <i>Clinical Infectious Diseases</i> , 2023, 76, 905-912.	2.9	9
65	Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers. <i>Journal of Infection</i> , 2021, 82, 151-161.	1.7	7
66	No evidence of industry sponsorship bias in statin trials. <i>BMJ</i> , The, 2014, 349, g6579-g6579.	3.0	6
67	Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT. <i>Programme Grants for Applied Research</i> , 2019, 7, 1-108.	0.4	6
68	Has <i>Chlamydia trachomatis</i> prevalence in young women in England, Scotland and Wales changed? Evidence from national probability surveys. <i>Epidemiology and Infection</i> , 2019, 147, e107.	1.0	4
69	Joint synthesis of conditionally related multiple outcomes makes better use of data than separate meta-analyses. <i>Research Synthesis Methods</i> , 2020, 11, 496-506.	4.2	3
70	Risk of reproductive complications following chlamydia testing. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1223-1224.	4.6	2
71	A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis. <i>Research Synthesis Methods</i> , 2022, 13, 573-584.	4.2	2
72	Heightened risk of false positives in a network meta-analysis of social anxiety "Author's reply. <i>Lancet Psychiatry</i> , the, 2015, 2, 293-294.	3.7	0

#	ARTICLE	IF	CITATIONS
73	Response to White and Lewis: Letter to editor in response to Has <i>Chlamydia trachomatis</i> prevalence in young women in England, Scotland and Wales changed? Evidence from national probability surveys. <i>Epidemiology and Infection</i> . 2019. <i>Epidemiology and Infection</i> , 2019, 147, e272.	1.0	0